ISSN: 1556-3790

Journal Home

Journal Guideline

Current Colorectal Cancer Reports Q3 Unclaimed

Springer Science + Business Media United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Current Colorectal Cancer Reports is a journal indexed in SJR in Oncology and Gastroenterology with an H index of 29. It has a price of 2590 €. It has an SJR impact factor of 0,272 and it has a best quartile of Q3. It is published in English. It has an SJR impact factor of 0,272.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Gastroenterology (Q3) Hepatology (Q3) Oncology (Q3)

Price

2590 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

0,272

SJR Impact factor

29

H Index

8

Total Docs (Last Year)

49

Total Docs (3 years)

396

Total Refs

42

Total Cites (3 years)

49

Citable Docs (3 years)

0.85

Cites/Doc (2 years)

49.5

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Cancer Management and Research Q3
Journal of Breast Cancer Q3
Breast Cancer: Basic and Clinical Research Q3
Oncology Letters Q3
Clinical Medicine Insights: Oncology Q3

Compare this journals

Aims and Scope

Best articles by citations

Should We Perform a New Adjuvant Trial with Bevacizumab?

Low Rectal Cancer: The Great Challenge for the Multidisciplinary Team - Contributions from High-Resolution Magnetic Resonance Imaging for the Correct Therapeutic Approach

Lymph node sampling for rectal cancer: How much is enough?

Preoperative Selection and Optimization for Liver Resection in Colorectal Cancer Liver Metastases

Why and How Should We Measure the Long-Term Consequences of Rectal Cancer Treatment?

The RNA-Binding Protein Musashi1: A Major Player in Intestinal Epithelium Renewal and Colon Cancer Development

New Neoadjuvant Treatment Strategies for Non-Metastatic Rectal Cancer (M0)

Is local excision adequate for stage I rectal cancer?

Future Solutions for Patients with Metastatic Colorectal Cancer Positive for K-RAS Mutations

Current Trends in the Management of Low Rectal Tumors: Transanal Total Mesorectal Excision

Quality of Life and Functions After Chemoradiation for Rectal Cancer: A Review of Recent Publications

What Is the Role of Lateral Lymph Node Excision in Patients with Locally Advanced Rectal Cancer Who Received Preoperative Chemoradiotherapy?

SHOW MORE ARTICLES

One Size Does Not Fit All: Planning Volumes for Radiotherapy in Rectal Cancer - Should We Tailor Radiotherapy Fields to Stage and Risk?

Overview of Microsatellite Instability and Immune Checkpoint Inhibitors in Colorectal Cancer

Prevention and Treatment of Colorectal Cancer by Natural Agents from Mother Nature

Clinical Reasons for Initiation of Adjuvant Phase III Trials on Colon Cancer

Markers in Colorectal Cancer and Clinical Trials Based Upon Them

Molecular Prognostic and Predictive Markers in Colorectal Cancer: Current Status

Clinical Relevance of Apoptotic Regulatory Proteins in Colorectal Cancers

The Outlook for Immune Checkpoint Targeting Strategies in Colorectal Cancer

Is There a Best Radiosensitizing Agent in the Treatment of Locally Advanced Rectal Cancer?

Use of Yttrium-90 Radioembolization for Management of Colorectal Liver Metastases

Polo-Like Kinases in Colorectal Cancer: Potential for Targeted Therapy

Chemoprevention of Colorectal Cancer in High-Risk Patients: from Molecular Targets to Clinical Trials